Feb 04, 2022
Rotterdam, The Netherlands
IMCD Pharmaceuticals experts discuss the latest advancements in cancer treatment
IMCD spoke with three of its experts in the Biopharma and API market sectors to discuss the latest developments in cancer treatment.
2020 was a year like no other: an unknown pathogen took over our lives, so much so that everything else seemed to take a back seat. However, one, in turn, meant that the introduction of new cancer treatments Whilst the pandemic caused a drive for immediate solutions, now it is time to look to the future with a focus on prevention,
IMCD spoke with three of its experts in the Biopharma and API market sectors – Sylvain Tamier, Dr Heeshma Shah and Dr Cristina Marti - to discuss the latest developments in cancer treatment. Sylvain Tamier, IMCD Biopharma Market Leader, has vast experience in this topic, from his previous position at AstraZeneca to his latest biopharma market development responsibilities at IMCD. Dr Heeshma Shah, IMCD Global Biopharma Technical Director, has been committed to bringing the best solutions to patients in India throughout her long career. Dr Cristina Marti, IMCD Director API Strategy,
We are hearing a lot about the advancements in cancer therapy and prevention. But what do you think is the most promising for patients suffering from cancer acutely or who are at risk of getting it?
What are the latest innovative therapies that you are most excited about?
Personalised treatment is driving positive advancements
Gene therapy for cancer treatment has seen good progress in the last three decades. Several drugs have been approved, while others are still in trials. Generally, gene therapy has better safety with more tolerable adverse effects than chemotherapy for the treatment of cancer. In the future, tumour genomic analysis, assessment of host humoral and cellular immunity will facilitate a better selection of the most appropriate patient for gene therapy. Recent progress in developing safe and effective vectors for gene delivery and understanding the activity of nucleases enables future genome editing as a new treatment approach for diseases like cancer.
While progress is being made, we recognise that there is still a long way to go. IMCD’s Pharmaceuticals team is dedicated to supporting and driving advancements in the treatment of this disease that affects so many people all over the world. We know there is still an ongoing fight against cancer, and at IMCD, we are striving to be more aware of how we can assist this battle with the products in our portfolio, but also through the initiatives we support around the world.